Cell Therapy Market: By Application (Musculoskeletal, Cardiovascular, Others) By Technology (Cell immortalization, Somatic cell, Others) By Cell Source (Induced pluripotent stem cells, Bone marrow, Others) By End User (Hospitals and clinics, Diagnostic centers, Others) Regional Analysis & Forecast - 2026

The most common and popular technique of cell therapy aims at using healthy cells from a compatible donor (Allogeneic) or from the patient itself (Autogenic) and their modification to amplify their therapeutic ability. The complex steps that are involved in it are the genetic screening of the cell, modification of a cell by genetic sequencing, their harvesting, and reinfusion into the patient's body. Each of these steps plays a key role in therapeutic development, this leads to the establishment of the global cell-based therapy market. Several indications have found to be curable with the help of cell therapies, and these indications are expected to increase in the near future. Cerebral disorders including Parkinson’s disease and Alzheimer’s disease are under investigation to treat with the help of cell therapies. They are also investigated for cardiovascular disease in which the aim is to restore normal heart functions.

Market Overview

The Global Cell Therapy Market size was valued at USD xx billion in 2018, and It is likely to grow at 13.1% CAGR during the forecast period. The increasing prevalence of chronic diseases and lifestyle disorders like cancer, cardiovascular, diabetes, arthritis, and epilepsy, is one of the major factors for the growth of the cell-based therapy market. The cell-based assays for the nervous system and chronic pain provide new opportunities for developing novel medicines for pain and neurodegenerative diseases. Cell-based assays are useful highly in screening mutagenesis in various types of cancers, such as chronic myeloid leukemia.

The rise in chronic diseases, in turn, raise the demand for cell-based assays for new drug discoveries, making it a key factor for the growth of the global market. Other factors playing a vital role for the growth of this market include increasing investments in R&D for drug discovery, technological advancements in cell-based methodologies, and rising adoption of high-throughput screening methods, particularly in toxicological studies. In addition, declining prices of stem cell therapies are leading to the increased inclination of buyers towards cell therapy.

The approval of first Cell Therapy, Carticel®, in 1997 in the US, has rapidly advanced and currently, a number of similar therapies are under development. The examples of approved cell-based therapies include CreaVax-RCC®, JACE, Carticel®, ReliNethra, Prochymal®, and Provenge®. As the majority of cell-based therapy products are in the early phase of development, several numbers of manufacturers are going to meet the clinical scale production requirements. In Feb. 2019, The US FDA and the Data and Safety Monitoring Board (DSMB) grants permission to resume enrolment of CAP 1002 in the phase II HOPE-2 study for Duchenne muscular dystrophy. U.S. Food and Drug Administration (FDA) expects more than 200 investigational new drug applications (IND) by 2020 per year, many of the cell and gene therapies, the agency issued an outline of new procedures it plans to implement this year.

Key Developments

• Feb 2019, Mesoblast announces an intention to conduct a meeting with the US FDA for BLA filing of Remestemcel-L for Graft-versus-host disease in April 2019.


• Also, in Feb 2019, Mesoblast announced an intention to conduct a meeting with the US FDA to discuss the potential approval pathway for rexlemestrocel-L in heart failure in the US in the second half of 2019.

Segmentation

The Global Cell Therapy market is segmented on the basis of type, technology, cell source, application, and end-user.

Based on Type: autologous and allogeneic.

Based on Technology: Cell immortalization technology, somatic cell technology, genome editing technology, cell plasticity technology, viral vector technology, and three-dimensional technology. The viral vector technology is further segmented into Ex vivo gene modification of cells and In vivo gene modification of cells.

Based on Cell source: Induced pluripotent stem cells (iPSCs), bone marrow, umbilical cord blood-derived cells, adipose tissue, and neural stem cell.

Based on Application: Musculoskeletal, cardiovascular, gastrointestinal, neurological, oncology, dermatology, wounds and injuries, ocular, and others.

Based on End-users: Hospital & clinics, diagnostic centers, regenerative medicine centers, research institutes, and others.

Based on Geographically: the Americas dominate the cell therapy market owing to high healthcare expenditure and the rise in awareness among people. Europe stands for the second position in the cell-based therapy market. It is anticipated that the support provided by government bodies for R&D and increase in reimbursement policies in healthcare is going to drive the market in the Europe region. The Asia Pacific is known to be the fastest-growing cell therapy market leading to a huge patient pool, developing healthcare technology and improving healthcare expenditure. The Middle East & Africa is found to have the lowest market for cell-based therapy because of the lack of technical knowledge and poor medical facilities.

Some of the key players in the Cell Therapy Market are Novartis AG, GlaxoSmithKline plc, Osiris, PHARMICELL, NuVasive, Inc., ANTEROGEN.CO. Ltd., Cynata, CELLECTIS, BioNTech IMFS, EUFETS GmbH, JCR Pharmaceuticals Co., Ltd, Cognate, Pluristem, Grupo Praxis, Genzyme Corporation, Advanced Tissue, and others.